Ironwood Pharmaceuticals (IRWD) 10-K2019 FY Annual report

Filed: 13 Feb 20, 4:21pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AA, AbbVie, aforementioned, AHP, AHRI, Alnylam, aminolevulinic, ancillary, Ardelyx, arrive, back, Bipartisan, bolster, cap, capped, CCPA, colocation, competitor, confer, declassification, declassified, declassify, delete, description, disregard, downtown, expert, fault, floor, formatted, furniture, gap, GIVLAARI, GIVLAARITM, givosiran, Hatch, hepatic, immunogenic, inaccurate, indemnity, Inline, Instance, ISBRELA, judgement, lieu, master, methodology, migrated, Modernization, monthly, move, NaN, opt, orderly, outdated, page, pilot, pivotal, porphyria, postponed, predetermined, procurement, quo, real, recast, redefine, redefining, refractory, reintroduction, Relocated, remanded, rentable, rescheduled, resold, RNAi, secretion, sNDA, Spread, subsidiary, Summer, superseded, surrendered, synthase, tegaserod, tenant, tenapanor, terminology, testify, topline, tract, unapproved, unbilled, unexpired, Unwind, Waxman, XBRL

Removed: absent, acceleration, Acceleron, accident, accidental, accretion, accruing, Achaogen, advancement, affirming, agonist, al, Alabama, Alimentary, allopurinol, Amgen, Amy, antibiotic, appointed, approach, Ardea, Astra, attain, automobile, bargain, baseline, belief, Berkeley, Biogen, biology, Biomedical, biopharmaceutical, blood, career, carryforward, category, cell, cGMP, collectability, College, comparative, complement, consolidate, contemplated, continuously, contrary, controlled, convenience, Counsel, covenant, creatinine, Cubist, cumulatively, cure, Currie, denosumab, depict, deposited, Deputy, diabetic, disclaimed, disposing, dosing, Dr, earn, Eleventh, environmental, esomeprazole, Eurasian, examination, exceeding, explain, Fanucci, FDC, fellow, Flom, founding, GC, Genzyme, Germany, Gilbert, glycol, grown, Halley, headache, heading, Hecht, heightened, holding, hyperuricemia, Idec, identification, implied, inflammation, inflammatory, influenza, injury, Institute, interrupt, IPO, issuable, Johanson, Johnson, joined, joining, judged, kidney, launching, leader, leadership, length, lengthened, lessee, liaison, LP, lump, MA, magnesium, magnitude, manager, managerial, marked, Marsha, maximizing, McGuire, Meagher, medicine, Merck, merge, mission, molecular, Monsanto, navigating, NCE, nephropathy, nitric, Northwestern, older, opposition, optionality, oversee, oxidase, oxide, panel, Pare, patentee, payer, Peter, pharmacology, Polyethylene, Prilosec, provisional, reach, reassessed, reconciling, recording, recoverability, recovery, repay, resell, responded, retained, rigorously, run, School, Schulman, secretary, secured, segregated, Sepracor, serum, shortened, Skadden, South, specialty, St, Stanford, sublet, sum, supported, sustain, symptom, talent, terminally, Terrance, tied, timeline, traditional, transformational, transplant, tumor, ulcerative, uncured, University, unvested, upheld, uric, utilizing, venue, Vol, waiver, Wake, Whitehead, wider, Wisconsin, worked, xanthine, XOI, younger

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated IRWD transcripts

IRWD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002

In connection with the Annual Report of Ironwood Pharmaceuticals, Inc. (the “Company”) on Form 10‑K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gina Consylman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, to my knowledge that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ GINA CONSYLMAN
Gina Consylman
Chief Financial Officer
February 13, 2020

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.